2022 March
archive,date,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive

March 2022

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et al. The lancet Oncology March 14, 2022)



Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death, 0.76; 95% CI, 0.63 to 0.93; P=0.008).

Front line therapy with the combo improved median overall survival by 1 year compared to letrozole alone.
(Ref: Hortobagyi et al.NEJM March 10, 2022.)


The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations. This data suggests new mechanisms of genomic escape from established covalent and novel noncovalent BTK inhibitors. (Ref: Wang E et al.NEJM, 2022)